A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943

A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 Versus Placebo on Calorie Intake and Energy Expenditure in Participants With Obesity Under Calorie Restriction

The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.

Inclusion Criteria:

• BMI greater than 30 kg/m2
• History of at least 1 self-reported unsuccessful dietary effort to reduce body weight

Exclusion Criteria:

• Change in body weight of greater than 5 kg (11 pounds) within 3 months prior to start of study
• Any of the following treatments for obesity within 1 year prior, or plan to undergo any of these during the study period: liposuction, cryolipolysis, or abdominoplasty
• Prior or planned bariatric or gastric sleeve surgery, endoscopic therapy, or device-based therapy for obesity
• Type 1 or Type 2 Diabetes, history of ketoacidosis, or hyperosmolar state
• Family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome Type 2
• Acute or chronic hepatitis
• Had within 90 days prior: acute myocardial infarction, cerebrovascular accident (stroke), coronary artery revascularization, hospitalization for unstable angina, or hospitalization due to congestive heart failure
• History of active or unstable major depressive disorder or other severe psychiatric disorder within 2 years prior
• History of chronic or acute pancreatitis
• Blood transfusion or severe blood loss within the last 3 months or hemoglobinopathy, hemolytic anemia, sickle cell anemia
• Clinically significant multiple or severe drug allergies
• Started treatment with or changed dose within 12 months prior any medications that are associated with significant weight gain
• History of substance use disorder